20 Nov PTK6 Inhibitors May Target Endocrine Therapy-Resistant ER+ Breast Cancer
MedicalResearch.com Interview with:
Hanna Irie MD PhD, senior author
Assistant Professor of Medicine
(Hematology and Medical Oncology) and Oncological Sciences at The Tisch Cancer Institute,
Icahn School of Medicine at Mount Sinai
MedicalResearch.com: What is the background for this study? What are the main findings?
Response: Our study identified PTK6 as a critical gene regulating survival of ER+ breast cancer cells.
PTK6 inhibition also suppresses growth and survival of ER+ breast cancer cells that are resistant to the effects of therapies commonly used to treat patient ER+ breast cancers, making PTK6 an attractive candidate therapeutic target for these resistant cancers.
MedicalResearch.com: What should clinicians and patients take away from your report?
Response: Additional studies validating PTK6 as a therapeutic target for ER+ breast cancer, the most common breast cancer subtype, are underway and could lead to a novel approach to treating these cancers.
MedicalResearch.com: What recommendations do you have for future research as a result of this study?
Response: We are planning to study the effects of different types of PTK6 inhibitors in cell line and animal models, which if successful could be translated clinically.
MedicalResearch.com: Thank you for your contribution to the MedicalResearch.com community.
PTK6 regulates growth and survival of endocrine therapy-resistant ER+ breast cancer cells
Koichi Ito, Sun Hee Park, Igor Katsyv, Weijia Zhang, Carmine De Angelis, Rachel Schiff & Hanna Y. Irie
npj Breast Cancer 3, Article number: 45 (2017)
Note: Content is Not intended as medical advice. Please consult your health care provider regarding your specific medical condition and questions.